# Citations for Research Query

**Query:** # Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Gout
- **MONDO ID:**  (if available)
- **Category:** Complex

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Gout**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs

**Provider:** falcon
**Generated:** 2025-12-17T23:40:58.334321

1. sanchez2024effectivexanthineoxidase pages 9-10
2. tan2024mechanismofmacrophages pages 11-12
3. tan2024mechanismofmacrophages pages 2-4
4. chen2024mechanismofneutrophil pages 8-8
5. herdiana2025currentstatusof pages 2-4
6. sanchez2024effectivexanthineoxidase pages 8-9
7. lin2024thetherapeuticmanagement pages 2-5
8. tesfaye2024empagliflozinandrisk pages 1-2
9. mccormick2024comparativeeffectivenessof pages 1-2
10. lin2024thetherapeuticmanagement pages 5-6
11. mccormick2023comparativeeffectivenessof pages 1-3
12. mccormick2023comparativeeffectivenessof pages 5-6
13. s
14. es
15. https://doi.org/10.1038/s42003-024-06534-6;
16. https://doi.org/10.1038/s42003-024-06534-6
17. https://doi.org/10.1016/j.heliyon.2024.e38288
18. https://doi.org/10.3389/fendo.2023.1071630
19. https://doi.org/10.1038/s41598-024-74154-5
20. https://doi.org/10.3390/gucdd2020016
21. https://doi.org/10.1093/rheumatology/keae420
22. https://doi.org/10.7326/m23-0724.
23. https://doi.org/10.1007/s11606-024-08793-9.
24. https://doi.org/10.1136/bmj-2024-080035
25. https://doi.org/10.55563/clinexprheumatol/ezzfbt
26. https://doi.org/10.1093/rheumatology/keae420.
27. https://doi.org/10.1136/bmj-2024-080035.
28. https://doi.org/10.1038/s41598-024-74154-5,
29. https://doi.org/10.3390/pharmaceutics17010102,
30. https://doi.org/10.1016/j.heliyon.2024.e38288,
31. https://doi.org/10.3390/ph17111507,
32. https://doi.org/10.55563/clinexprheumatol/ezzfbt,
33. https://doi.org/10.7326/m23-0724,
34. https://doi.org/10.1007/s11606-024-08793-9,
35. https://doi.org/10.1136/bmj-2024-080035,